Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?
نویسندگان
چکیده
منابع مشابه
UBE2Q1, as Down Regulated Gene in Pediatric Acute Lymphoblastic Leukemia
Ubiquitin - proteasome system (UPS), the major protein degradation pathway in the cells, typically degrades short - lived and damaged proteins and regulates growth and stress responses. This pathway is altered in various cancers, including Acute Lymphoblastic Leukemia (ALL). ALL begins with a change in bone marrow cells and is the most common type of leukemia in children under 15 years. UBE2Q1...
متن کاملPediatric Acute Lymphoblastic Leukemia
Results ETV6/RUNX1 had a strong effect on overall survival after relapse (3-year survival= 64.7% for positive cases versus 46.5% for negative cases) (P=0.007). The 5-year cumulative incidence of relapse was 19.4% and testes were more frequently involved in ETV6/RUNX1-positive relapses (P=0.04). In 81.4% of cases the relapses were late, early combined or isolated extramedullary relapses. The 5-y...
متن کاملPediatric Acute Lymphoblastic Leukemia
This review will focus on pediatric acute lymphoblastic leukemia (pALL), highlighting risk factors, classification, presentation, risk group assignment and treatment stratification, treatment, outcome, and long-term consequences of therapy. Other forms of pediatric leukemia, such as acute and chronic myeloid leukemia are not reviewed. The reader is referred to several recent publications review...
متن کاملPediatric acute lymphoblastic leukemia.
The outcome for children with acute lymphoblastic leukemia (ALL) has improved dramatically with current therapy resulting in an event free survival exceeding 75% for most patients. However significant challenges remain including developing better methods to predict which patients can be cured with less toxic treatment and which ones will benefit from augmented therapy. In addition, 25% of patie...
متن کاملAdult Acute Lymphoblastic Leukemia.
Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL) results in high cure rates in pediatric patients but is suboptimal in the treatment of adult patients. The 5-year overall survival is approximately 90% in children and 30% to 40% in adults and elderly patients. Adults with ALL tend to have higher risk factors at diagnosis, more comorbidities, and increasing age...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematology
سال: 2019
ISSN: 1520-4391,1520-4383
DOI: 10.1182/hematology.2019000009